肺部治疗市场－全球产业规模、份额、趋势、机会及预测（依疾病类型、治疗类型、药物类别、地区及竞争格局划分，2021-2031年）

全球肺部疾病药物市场预计将从 2025 年的 1,042.6 亿美元成长到 2031 年的 1,473.1 亿美元，复合年增长率达到 5.93%。

此细分市场包括用于治疗气喘、慢性阻塞性肺病和肺纤维化等呼吸系统疾病的药品和生物製药，例如支气管扩张剂和皮质类固醇。市场扩张的主要驱动因素是呼吸系统疾病发生率的上升，而这又归因于快速的都市化、日益严重的环境污染以及人口老化（老年人更容易患慢性病）。美国肺臟协会强调了环境因素的影响，其报告指出，到2024年，美国约有1.31亿人将居住在空气污染水平不健康的地区，凸显了有效呼吸系统治疗的紧迫性。

儘管前景广阔，但由于研发和生产复杂生物药物需要巨额资金，市场仍面临许多障碍。这些高昂的研发成本，加上严格的监管核准流程，往往会延缓新治疗方法的上市，并限制价格敏感型市场患者的用药机会，从而阻碍全球治疗行业的全面发展。

市场驱动因素

在全球范围内，因持续吸烟导致的慢性呼吸系统疾病日益增多，这已成为治疗药物市场的主要驱动力。吸烟会显着损害肺功能，导致慢性阻塞性肺病（COPD）等疾病，这些疾病需要长期药物治疗。尼古丁的成瘾性维持了这种需求。正如世界卫生组织（世卫组织）2024年5月发布的《烟草》关键情况说明书中所述，烟草每年导致超过800万人死亡，其中包括130万因二手烟而死亡的非吸烟者。因此，吸烟相关疾病的负担迫切需要我们持续研发治疗方法，以控制症状并改善患者健康。

此外，生物製药和标靶治疗的技术进步正在改变呼吸系统疾病的治疗格局，为难以控制的呼吸系统疾病提供超越传统症状管理的解决方案。这些先进的生物製药可针对治疗重度气喘和慢性阻塞性肺病（COPD）等疾病中的特定发炎通路，显着降低病情加重率和住院率。例如，再生元製药公司在2024年9月的新闻稿中宣布，其生物製药可将COPD患者的中重度病情加重率降低34%。这种向精准医疗的转变得到了大量产业投资的支持，例如Astra Zeneca在2024年宣布，将投资15大规模美元在新加坡建造一座专门用于抗体药物复合体和标靶治疗的工厂。

市场挑战

开发和生产复杂生物製药所需的大量资本支出和严格的监管核准流程，对全球肺部治疗领域的进步构成了重大障碍。临床研究和专业生产所需的巨额投资迫使製药公司对先进治疗方法进行极具竞争力的定价以收回成本。这限制了其在对成本敏感地区的市场渗透率，并使许多患者无法获得治疗。此外，这些投资带来的巨大财务风险也阻碍了小众市场或高风险呼吸系统疾病新型作用机制的研究，有效扼杀了创新。

最新的产业数据显示，这一巨大的经济负担凸显了该领域面临的盈利挑战。根据国际药品製造商协会联合会（IFPMA）2024年的数据，新药研发的平均成本预计已达26亿美元。如此巨额的成本直接阻碍了市场扩张，提高了准入门槛，延缓了创新生物製药的上市进程，而这些药物对于治疗气喘和慢性阻塞性肺病等疾病至关重要。

市场趋势

智慧吸入器和互联数位疗法的引入正在改变患者照护，提高用药依从性并提供即时生理数据。这些技术利用感测器设备监测使用模式和吸气流量，使医疗专业人员能够客製化干预措施，避免慢性呼吸系统疾病的加重。互联医疗领域强劲的财务表现也支撑了这一数位转型。例如，在2024年8月的公布财报上，ResMed公司报告称，其营收成长9%至12亿美元，这主要得益于市场对其云端连接睡眠和呼吸照护解决方案的持续需求。

同时，针对罕见呼吸系统疾病的疾病修正治疗正日益受到关注，治疗重点也从缓解症状转向标靶化潜在的基因缺陷。製药公司正大力投资小分子矫正剂和增强剂，以纠正囊肿纤维化等疾病中的特定蛋白质功能障碍，从而显着改善肺功能和患者存活率。这一策略方向也体现在市场领导的财务成功上。 Vertex Pharmaceuticals 在 2024 年 11 月的报告中宣布，其产品收入增长 12%，达到 27.7 亿美元，这主要得益于该公司专门针对囊肿纤维化的疗法在全球范围内的广泛应用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球肺部疾病药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依疾病类型（气喘、肺癌、慢性阻塞性肺病）
  • 依治疗方法（化疗、免疫疗法、标靶治疗、放射线治疗）
  • 依药物类别（皮质类固醇、支气管扩张剂、抗生素、烷化剂、祛痰药）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美肺部药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲肺部药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区肺部药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲肺部疾病药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美肺病药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球肺部药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Novartis AG
• Johnson & Johnson Services, Inc.
• Amgen Inc.
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Pfizer Inc.
• Allergan Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F Hoffmann-La Roche Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Lung Disease Therapeutics Market is projected to expand from USD 104.26 Billion in 2025 to USD 147.31 Billion by 2031, achieving a compound annual growth rate of 5.93%. This sector comprises pharmaceutical formulations and biological agents, including bronchodilators and corticosteroids, intended to treat respiratory pathologies such as asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis. Market expansion is chiefly driven by the rising incidence of respiratory disorders caused by rapid urbanization, escalating environmental pollution, and a growing aging population prone to chronic ailments. Highlighting the impact of environmental factors, the American Lung Association reported in 2024 that approximately 131 million people in the United States resided in areas with unhealthy air pollution levels, emphasizing the urgent need for effective respiratory treatments.

Despite these growth prospects, the market confronts a major obstacle regarding the immense capital needed to develop and manufacture complex biologic drugs. These significant development expenditures, combined with strict regulatory approval processes, often postpone the launch of new therapies and restrict patient access in price-sensitive markets, thereby impeding the broader growth of the global therapeutics industry.

Market Driver

The increasing global prevalence of chronic respiratory diseases, driven by ongoing tobacco use, acts as a primary catalyst for the therapeutics market. Smoking severely impairs lung function, resulting in conditions like chronic obstructive pulmonary disease that require prolonged pharmacological intervention, a demand sustained by the addictive nature of nicotine. As noted in the World Health Organization's 'Tobacco' key facts sheet from May 2024, tobacco causes over 8 million deaths annually, including 1.3 million non-smokers affected by second-hand smoke; consequently, the smoking-related disease burden necessitates the continual development of therapeutic measures to manage symptoms and enhance patient well-being.

Furthermore, technological progress in biologics and targeted therapies is transforming the treatment landscape by providing solutions for uncontrolled respiratory conditions that go beyond traditional symptom management. These advanced biologics target specific inflammatory pathways in diseases like severe asthma and chronic obstructive pulmonary disease, significantly lowering exacerbation rates and hospitalizations. For instance, Regeneron Pharmaceuticals announced in a September 2024 press release that their biologic reduced moderate-to-severe exacerbation rates by 34 percent in COPD patients. This move toward precision medicine is backed by massive industrial investment, such as AstraZeneca's 2024 announcement of a USD 1.5 billion investment to build a Singapore facility dedicated to antibody-drug conjugates and targeted therapies.

Market Challenge

The substantial capital required for developing and manufacturing complex biologic drugs, along with stringent regulatory approval procedures, presents a significant barrier to the advancement of the global lung disease therapeutics sector. The immense financial outlay necessary for clinical research and specialized production compels pharmaceutical firms to set premium prices for advanced therapies to recoup costs, which limits market penetration in cost-sensitive areas and restricts access for many patients. Additionally, the considerable financial risks involved in these investments deter the pursuit of novel mechanisms of action for respiratory pathologies with smaller or riskier markets, effectively stalling innovation.

The severity of this financial burden is highlighted by recent industry data, which underscores the high threshold for profitability in the sector. According to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in 2024, the estimated average cost to develop a new medicine reached USD 2.6 billion. This enormous expense directly hinders market expansion by raising the barrier to entry and slowing the introduction of innovative biologics essential for treating conditions such as asthma and chronic obstructive pulmonary disease.

Market Trends

The incorporation of smart inhalers and connected digital therapeutics is transforming patient care by improving medication adherence and supplying real-time physiological insights. These technologies employ sensor-enabled devices to monitor usage patterns and inspiratory flow, enabling healthcare professionals to customize interventions and avert exacerbations in chronic respiratory conditions. This digital shift is validated by robust financial results in the connected care domain; for example, ResMed reported in its August 2024 earnings release that revenue grew by 9 percent to USD 1.2 billion, fueled by persistent demand for its cloud-connected sleep and respiratory care solutions.

Concurrently, there is a heightened emphasis on disease-modifying therapies for rare respiratory disorders, transitioning the treatment focus from symptomatic relief to targeting root genetic defects. Pharmaceutical companies are heavily investing in small molecule correctors and potentiators that rectify specific protein malfunctions in conditions like cystic fibrosis, thereby significantly enhancing lung function and patient survival. This strategic direction is reflected in the financial success of market leaders; Vertex Pharmaceuticals, in its November 2024 report, announced a 12 percent increase in product revenue to USD 2.77 billion, largely driven by the widespread global adoption of its specialized cystic fibrosis treatments.

Key Market Players

• Novartis AG
• Johnson & Johnson Services, Inc.
• Amgen Inc.
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Pfizer Inc.
• Allergan Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F Hoffmann-La Roche Ltd.

Report Scope

In this report, the Global Lung Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Disease Therapeutics Market, By Disease Type

• Asthma
• Lung Cancer
• Chronic Obstructive Pulmonary Disease

Lung Disease Therapeutics Market, By Treatment Type

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy

Lung Disease Therapeutics Market, By Drug Class

• Corticosteroids
• Bronchodilator
• Antimicrobial
• Alkylating Agents
• Mucolytics

Lung Disease Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Disease Therapeutics Market.

Available Customizations:

Global Lung Disease Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Disease Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Asthma, Lung Cancer, Chronic Obstructive Pulmonary Disease)
  • 5.2.2. By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy)
  • 5.2.3. By Drug Class (Corticosteroids, Bronchodilator, Antimicrobial, Alkylating Agents, Mucolytics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Lung Disease Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By Drug Class
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lung Disease Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Drug Class
  • 6.3.2. Canada Lung Disease Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Drug Class
  • 6.3.3. Mexico Lung Disease Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Drug Class

7. Europe Lung Disease Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By Drug Class
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lung Disease Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Drug Class
  • 7.3.2. France Lung Disease Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Drug Class
  • 7.3.3. United Kingdom Lung Disease Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Drug Class
  • 7.3.4. Italy Lung Disease Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Drug Class
  • 7.3.5. Spain Lung Disease Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Drug Class

8. Asia Pacific Lung Disease Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By Drug Class
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lung Disease Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Drug Class
  • 8.3.2. India Lung Disease Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Drug Class
  • 8.3.3. Japan Lung Disease Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Drug Class
  • 8.3.4. South Korea Lung Disease Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Drug Class
  • 8.3.5. Australia Lung Disease Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Drug Class

9. Middle East & Africa Lung Disease Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By Drug Class
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lung Disease Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Drug Class
  • 9.3.2. UAE Lung Disease Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Drug Class
  • 9.3.3. South Africa Lung Disease Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Drug Class

10. South America Lung Disease Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By Drug Class
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lung Disease Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Drug Class
  • 10.3.2. Colombia Lung Disease Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Drug Class
  • 10.3.3. Argentina Lung Disease Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Drug Class

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lung Disease Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Johnson & Johnson Services, Inc.
• 15.3. Amgen Inc.
• 15.4. AstraZeneca Plc
• 15.5. Boehringer Ingelheim International GmbH
• 15.6. Pfizer Inc.
• 15.7. Allergan Inc.
• 15.8. Bristol-Myers Squibb Company
• 15.9. Eli Lilly and Company
• 15.10. F Hoffmann-La Roche Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer